It has been reported that 50-100% of DM patients with anti-MDA5 developed ILD, and 39-71% of DM patients with anti-MDA5 developed RP-ILD (Chen et al., 2013; Abe et al., 2017; Moghadam-Kia et al., 2017). Here, IFIH1 is linked to interstitial lung disease.